首页 > 最新文献

Clinical and Investigative Medicine最新文献

英文 中文
Serum Interleukin Levels Predict Occurrence of Acute Radiation Pneumonitis and Overall Survival in Thoracic Tumours. 血清白细胞介素水平预测急性放射性肺炎的发生和胸部肿瘤的总生存期。
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 DOI: 10.3138/cim-2024-0262
Yan Zhang, Wen-Xiang Shen, Ping Li, Min-Bin Chen, Li-Na Zhou

Background: Radiation-induced lung injury (RILI) is a significant adverse effect of thoracic radiotherapy, potentially impacting patient prognosis. The risk factors for acute radiation pneumonitis (RP) have not been fully clarified. The present study evaluated the predictive value of serum interleukins (ILs) in the occurrence of RP and overall survival in patients with thoracic cancers.

Methods: This single-centre retrospective observational study enrolled 435 thoracic cancer patients who underwent chest radiation therapy. Serum levels of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17, TNF-α, IFN-γ, IFN-α were measured by cytometric bead array before radiotherapy. The relationship between clinical characteristics, serum IL levels and the occurrence of RP were analyzed. Cox regression and Kaplan-Meier methods were also performed to investigate the prognostic role of serum IL levels in these patients.

Results: The incidence of RP in these patients was 17.01%. Elevated serum levels of IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, TNF-α, IFN-α were all associated with the occurrence of RP. High levels of IL-1β, IL-4, and IL-12p70 were correlated with more severe pneumonitis. Univariate and multivariate logistic regression analysis identified serum IL-6 level as an independent prognostic factor in patients receiving thoracic radiotherapy.

Conclusions: Serum interleukin levels are linked to the development of acute RP in patients receiving thoracic radiotherapy. Serum IL-6 could serve as a valuable biomarker in identifying patients at high risk for RP, potentially guiding individualized therapeutic strategies and improving patient management in radiotherapy. Future research should focus on validating IL-6's role in larger cohorts and exploring its integration into clinical practice for the early prediction of RILI.

背景:放射性肺损伤(RILI)是胸部放射治疗的重要不良反应,可能影响患者预后。急性放射性肺炎(RP)的危险因素尚未完全明确。本研究评估了血清白介素(il)对胸部肿瘤患者RP发生和总生存率的预测价值。方法:这项单中心回顾性观察性研究纳入了435例接受胸部放疗的胸部肿瘤患者。采用细胞头阵列法检测放疗前血清IL-1β、IL-2、IL-4、IL-5、IL-6、IL-8、IL-10、IL-12p70、IL-17、TNF-α、IFN-γ、IFN-α水平。分析临床特征、血清IL水平与RP发生的关系。采用Cox回归和Kaplan-Meier方法探讨血清IL水平对患者预后的影响。结果:RP的发生率为17.01%。血清IL-1β、IL-2、IL-4、IL-6、IL-8、IL-10、IL-12p70、TNF-α、IFN-α水平升高均与RP的发生有关。高水平的IL-1β、IL-4和IL-12p70与更严重的肺炎相关。单因素和多因素logistic回归分析发现血清IL-6水平是接受胸部放疗患者的独立预后因素。结论:血清白细胞介素水平与胸部放疗患者急性RP的发展有关。血清IL-6可作为识别RP高危患者的有价值的生物标志物,潜在地指导个体化治疗策略和改善患者放疗管理。未来的研究应侧重于在更大的队列中验证IL-6的作用,并探索其与临床实践的结合,以早期预测RILI。
{"title":"Serum Interleukin Levels Predict Occurrence of Acute Radiation Pneumonitis and Overall Survival in Thoracic Tumours.","authors":"Yan Zhang, Wen-Xiang Shen, Ping Li, Min-Bin Chen, Li-Na Zhou","doi":"10.3138/cim-2024-0262","DOIUrl":"10.3138/cim-2024-0262","url":null,"abstract":"<p><strong>Background: </strong>Radiation-induced lung injury (RILI) is a significant adverse effect of thoracic radiotherapy, potentially impacting patient prognosis. The risk factors for acute radiation pneumonitis (RP) have not been fully clarified. The present study evaluated the predictive value of serum interleukins (ILs) in the occurrence of RP and overall survival in patients with thoracic cancers.</p><p><strong>Methods: </strong>This single-centre retrospective observational study enrolled 435 thoracic cancer patients who underwent chest radiation therapy. Serum levels of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17, TNF-α, IFN-γ, IFN-α were measured by cytometric bead array before radiotherapy. The relationship between clinical characteristics, serum IL levels and the occurrence of RP were analyzed. Cox regression and Kaplan-Meier methods were also performed to investigate the prognostic role of serum IL levels in these patients.</p><p><strong>Results: </strong>The incidence of RP in these patients was 17.01%. Elevated serum levels of IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, TNF-α, IFN-α were all associated with the occurrence of RP. High levels of IL-1β, IL-4, and IL-12p70 were correlated with more severe pneumonitis. Univariate and multivariate logistic regression analysis identified serum IL-6 level as an independent prognostic factor in patients receiving thoracic radiotherapy.</p><p><strong>Conclusions: </strong>Serum interleukin levels are linked to the development of acute RP in patients receiving thoracic radiotherapy. Serum IL-6 could serve as a valuable biomarker in identifying patients at high risk for RP, potentially guiding individualized therapeutic strategies and improving patient management in radiotherapy. Future research should focus on validating IL-6's role in larger cohorts and exploring its integration into clinical practice for the early prediction of RILI.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"48 1","pages":"29-38"},"PeriodicalIF":1.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143702105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significance of combined screening for GADA, ICA, and IAA in new-onset type 2 diabetes mellitus in adults for early diagnosis of latent autoimmune diabetes. 新发成人2型糖尿病GADA、ICA、IAA联合筛查对早期诊断潜伏性自身免疫性糖尿病的意义
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 DOI: 10.3138/cim-2024-0157
Shiqi Sun, Xiaobo Shen, Qi Huang, Jiazhong Sun

Purpose: To investigate the detection rate of latent autoimmune diabetes in adults (LADA) among newly diagnosed type 2 diabetes mellitus (T2DM) patients and analyze their clinical characteristics, with the aim of guiding treatment and improving prognosis.

Methods: Glutamic acid decarboxylase autoantibody (GADA), islet cell autoantibody (ICA), insulin autoantibody (IAA), blood pressure, height, weight, and BMI, as well as lipid profiles, fasting plasma glucose, insulin, C-peptide, HbA1c, thyroid-stimulating hormone (TSH), thyroglobulin antibody (TGAb), and thyroid peroxidase antibody (TPOAb) levels were measured in 352 newly diagnosed T2DM patients with disease duration of less than 1 year and non-ketotic onset. The incidence of LADA was calculated, and clinical characteristics of these patients were compared with those of T2DM patients without autoantibodies.

Results: The detection rate of LADA was 7.10%. Among the 25 LADA patients, 22 had GADA, 5 had ICA, 2 had IAA, and 2 were positive for all three antibodies. The percentages of GADA, ICA, and IAA among LADA patients were 88.00%, 20.00%, and 8.00%, respectively. Compared with the autoantibody-negative group, LADA patients had lower BMIs and total cholesterol, lower insulin and C-peptide levels, higher neutrophil counts, and increased abnormal TSH levels and TPOAb positivity (P < 0.05). LADA patients exhibited reduced CD4+ T cell expression levels, which were lower than those in patients without autoantibodies, while LADA patients' CD8+ T cell levels were within the normal range and slightly higher than those in patients without autoantibodies, reflecting a lower CD4+/CD8+ ratio in LADA patients.

Conclusion: A proportion of newly diagnosed T2DM patients have LADA. Early screening for GADA, ICA, and IAA should be performed in newly diagnosed T2DM patients with low BMI and poor islet function. LADA patients may have higher expression of inflammatory immune factors, lower total cholesterol, and a lower CD4+/CD8+ ratio. The decline in [Formula: see text]-cell function in LADA patients may be associated with decreased CD4+ T cell expression.

目的:了解新诊断2型糖尿病(T2DM)患者成人潜伏性自身免疫性糖尿病(LADA)检出率,分析其临床特点,以指导治疗和改善预后。方法:对352例病程小于1年、非酮症发病的新诊断T2DM患者,检测谷氨酸脱羧酶自身抗体(GADA)、胰岛细胞自身抗体(ICA)、胰岛素自身抗体(IAA)、血压、身高、体重、BMI以及血脂、空腹血糖、胰岛素、c肽、HbA1c、促甲状腺激素(TSH)、甲状腺球蛋白抗体(TGAb)、甲状腺过氧化物酶抗体(TPOAb)水平。计算LADA发生率,并与无自身抗体的T2DM患者的临床特征进行比较。结果:LADA检出率为7.10%。25例LADA患者中,22例为GADA, 5例为ICA, 2例为IAA, 2例三种抗体均阳性。LADA患者中GADA、ICA和IAA的比例分别为88.00%、20.00%和8.00%。与自身抗体阴性组比较,LADA患者bmi、总胆固醇降低,胰岛素、c肽水平降低,中性粒细胞计数升高,TSH异常水平和TPOAb阳性升高(P < 0.05)。LADA患者CD4+ T细胞表达水平降低,低于无自身抗体患者,而CD8+ T细胞表达水平在正常范围内,略高于无自身抗体患者,反映了LADA患者CD4+/CD8+比值较低。结论:新诊断T2DM患者中有一定比例存在LADA。对于低BMI和胰岛功能差的新诊断T2DM患者,应进行GADA、ICA和IAA早期筛查。LADA患者可能有较高的炎症免疫因子表达、较低的总胆固醇、较低的CD4+/CD8+比值。LADA患者的细胞功能下降可能与CD4+ T细胞表达下降有关。
{"title":"Significance of combined screening for GADA, ICA, and IAA in new-onset type 2 diabetes mellitus in adults for early diagnosis of latent autoimmune diabetes.","authors":"Shiqi Sun, Xiaobo Shen, Qi Huang, Jiazhong Sun","doi":"10.3138/cim-2024-0157","DOIUrl":"10.3138/cim-2024-0157","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the detection rate of latent autoimmune diabetes in adults (LADA) among newly diagnosed type 2 diabetes mellitus (T2DM) patients and analyze their clinical characteristics, with the aim of guiding treatment and improving prognosis.</p><p><strong>Methods: </strong>Glutamic acid decarboxylase autoantibody (GADA), islet cell autoantibody (ICA), insulin autoantibody (IAA), blood pressure, height, weight, and BMI, as well as lipid profiles, fasting plasma glucose, insulin, C-peptide, HbA<sub>1c</sub>, thyroid-stimulating hormone (TSH), thyroglobulin antibody (TGAb), and thyroid peroxidase antibody (TPOAb) levels were measured in 352 newly diagnosed T2DM patients with disease duration of less than 1 year and non-ketotic onset. The incidence of LADA was calculated, and clinical characteristics of these patients were compared with those of T2DM patients without autoantibodies.</p><p><strong>Results: </strong>The detection rate of LADA was 7.10%. Among the 25 LADA patients, 22 had GADA, 5 had ICA, 2 had IAA, and 2 were positive for all three antibodies. The percentages of GADA, ICA, and IAA among LADA patients were 88.00%, 20.00%, and 8.00%, respectively. Compared with the autoantibody-negative group, LADA patients had lower BMIs and total cholesterol, lower insulin and C-peptide levels, higher neutrophil counts, and increased abnormal TSH levels and TPOAb positivity (<i>P</i> < 0.05). LADA patients exhibited reduced CD4<sup>+</sup> T cell expression levels, which were lower than those in patients without autoantibodies, while LADA patients' CD8<sup>+</sup> T cell levels were within the normal range and slightly higher than those in patients without autoantibodies, reflecting a lower CD4<sup>+</sup>/CD8<sup>+</sup> ratio in LADA patients.</p><p><strong>Conclusion: </strong>A proportion of newly diagnosed T2DM patients have LADA. Early screening for GADA, ICA, and IAA should be performed in newly diagnosed T2DM patients with low BMI and poor islet function. LADA patients may have higher expression of inflammatory immune factors, lower total cholesterol, and a lower CD4<sup>+</sup>/CD8<sup>+</sup> ratio. The decline in [Formula: see text]-cell function in LADA patients may be associated with decreased CD4<sup>+</sup> T cell expression.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"48 1","pages":"24-28"},"PeriodicalIF":1.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143702106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overview of the Canadian Clinician Investigator Trainees' Research Presented at the 2024 CSCI-CITAC Joint Meeting. 加拿大临床研究员实习生在2024年CSCI-CITAC联席会议上的研究综述
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.3138/CIM-47-4-REPORT
MohdWessam Al Jawhri, Salonee V Patel, Shubham Soni, Richard Huang, Robert X Lao

The 2024 Annual Joint Meeting (AJM) and Young Investigators' Forum of the Canadian Society for Clinical Investigation (CSCI) and Clinician Investigator Trainee Association of Canada (CITAC) was held on April 11, 2024, in Vancouver, British Columbia. Hosted in collaboration with the University of British Columbia (UBC) and the International Congress on Academic Medicine (ICAM), this meeting marked a significant opportunity for clinician investigator trainees to present their research and connect with national and international peers. The event included 70 trainees, consisting of 58 MD+ (MD/PhD, MD and PhD, MD-MSc, MD and MSc) and 12 Clinician Investigator Program and/or Surgeon-Scientist Training Program trainees. The keynote speaker, Dr. Marco Marra, delivered a presentation titled "From C. elegans Genetics to Precision Cancer Genomic Medicine, via the Human Genome Project: Reflections on a Collaborative Scientific Journey." Dr. Kenneth Rockwood (Dalhousie University) received the CSCI Distinguished Scientist Award, and Dr. Bertrand Routy (Université de Montréal) received the CSCI Joe Doupe Young Investigator Award. Over 60 abstracts were showcased, most of which are summarized in this review, and six were selected for oral presentations. Following the AJM, trainees participated in ICAM's three-day health research program, where three AJM attendees were recognized among the top four presenters and were invited to the 2024 Canada Gairdner Awards Gala, with one of our AJM attendees winning the competition and being named the next Lindau Nobel Laurate Meetings Nominee.

加拿大临床研究学会(CSCI)和加拿大临床研究员培训协会(CITAC) 2024年年度联席会议(AJM)和青年研究者论坛于2024年4月11日在不列颠哥伦比亚省温哥华举行。本次会议由英属哥伦比亚大学(UBC)和国际学术医学大会(ICAM)联合主办,为临床研究员实习生提供了一个重要的机会来展示他们的研究成果,并与国内和国际同行建立联系。该活动包括70名学员,包括58名MD+ (MD/PhD, MD和PhD, MD-MSc, MD和MSc)和12名临床研究员项目和/或外科科学家培训项目学员。主讲人Marco Marra博士发表了题为“从秀丽隐杆线虫遗传学到精确的癌症基因组医学,通过人类基因组计划:对合作科学之旅的反思”的演讲。Kenneth Rockwood博士(Dalhousie University)获得CSCI杰出科学家奖,Bertrand Routy博士(universit de montrachim)获得CSCI Joe Doupe青年研究者奖。60多篇摘要被展示,其中大部分在本综述中进行了总结,并选择了6篇进行口头报告。在AJM之后,学员们参加了ICAM为期三天的健康研究项目,其中三名AJM与会者被认可为前四名演讲者,并被邀请参加2024年加拿大盖尔德纳奖颁奖晚会,其中一名AJM与会者赢得了比赛,并被提名为下一届林道诺贝尔奖获得者会议提名人。
{"title":"Overview of the Canadian Clinician Investigator Trainees' Research Presented at the 2024 CSCI-CITAC Joint Meeting.","authors":"MohdWessam Al Jawhri, Salonee V Patel, Shubham Soni, Richard Huang, Robert X Lao","doi":"10.3138/CIM-47-4-REPORT","DOIUrl":"10.3138/CIM-47-4-REPORT","url":null,"abstract":"<p><p>The 2024 Annual Joint Meeting (AJM) and Young Investigators' Forum of the Canadian Society for Clinical Investigation (CSCI) and Clinician Investigator Trainee Association of Canada (CITAC) was held on April 11, 2024, in Vancouver, British Columbia. Hosted in collaboration with the University of British Columbia (UBC) and the International Congress on Academic Medicine (ICAM), this meeting marked a significant opportunity for clinician investigator trainees to present their research and connect with national and international peers. The event included 70 trainees, consisting of 58 MD+ (MD/PhD, MD and PhD, MD-MSc, MD and MSc) and 12 Clinician Investigator Program and/or Surgeon-Scientist Training Program trainees. The keynote speaker, Dr. Marco Marra, delivered a presentation titled \"From <i>C. elegans</i> Genetics to Precision Cancer Genomic Medicine, via the Human Genome Project: Reflections on a Collaborative Scientific Journey.\" Dr. Kenneth Rockwood (Dalhousie University) received the CSCI Distinguished Scientist Award, and Dr. Bertrand Routy (Université de Montréal) received the CSCI Joe Doupe Young Investigator Award. Over 60 abstracts were showcased, most of which are summarized in this review, and six were selected for oral presentations. Following the AJM, trainees participated in ICAM's three-day health research program, where three AJM attendees were recognized among the top four presenters and were invited to the 2024 Canada Gairdner Awards Gala, with one of our AJM attendees winning the competition and being named the next Lindau Nobel Laurate Meetings Nominee.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 4","pages":"3-10"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CIM-CITAC Publication Award. CIM-CITAC出版物奖。
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.3138/CIM-47-4-AWARD
{"title":"CIM-CITAC Publication Award.","authors":"","doi":"10.3138/CIM-47-4-AWARD","DOIUrl":"https://doi.org/10.3138/CIM-47-4-AWARD","url":null,"abstract":"","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 4","pages":"2"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New CIM Editor-in-Chief. 新任CIM总编辑。
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.3138/CIM-47-4-ANNOUNCEMENT
{"title":"New CIM Editor-in-Chief.","authors":"","doi":"10.3138/CIM-47-4-ANNOUNCEMENT","DOIUrl":"https://doi.org/10.3138/CIM-47-4-ANNOUNCEMENT","url":null,"abstract":"","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 4","pages":"1"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of miR-34a on Endothelial Cell Viability and Apoptosis in Ischemic Stroke: Unraveling the MTHFR-Homocysteine Pathway. 缺血性中风中 miR-34a 对内皮细胞活力和凋亡的影响:揭秘 MTHFR-同型半胱氨酸通路
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-01 Epub Date: 2024-08-27 DOI: 10.3138/cim-2024-2711
Lina Liang, Xueli Yi, Chunfang Wang, Li Su, Guijiang Wei

Introduction: Ischemic stroke (IS) is a global health concern, often tied to dyslipidemia and vascular endothelial dysfunction. MicroRNA-34a (miR-34a) was reported to be up-regulated in the blood samples of patients with IS, but the specific role of miR-34a and methylenetetrahydrofolate reductase (MTHFR) in IS remains to be elucidated.

Methods: We studied 143 subjects: 71 IS patients, and 72 healthy controls. Human umbilical vein endothelial cells (HUVECs) were cultured and transfected with a miR-34a mimic, inhibitor, or negative control. The miR-34a expression in serum and HUVECs was quantified via quantitative reverse transcription polymerase chain reaction (qRT-PCR). Viability and apoptosis of HUVECs were assessed using CCK-8 assay and flow cytometry. The expression levels of bcl-2, bax, cyt-c, cleaved caspase 3, MTHFR, and homocysteine were measured by Western blot or enzyme-linked immunosorbent assay (ELISA). The relationship between miR-34a and MTHFR was verified by luciferase reporter assay. The levels of MTHFR and homocysteine in serum were examined by ELISA.

Results: MiR-34a expression was increased in IS patients and inhibited viability of HUVECs while promoting their apoptosis. Overexpression of miR-34a up-regulated pro-apoptotic proteins (bax, cyt-c and cleaved caspase 3) and down-regulated anti-apoptotic protein bcl-2 in HUVECs. MTHFR was identified as the downstream target of miR-34a and its expression was reduced by miR-34a overexpression, while homocysteine levels increased. Consistently, MTHFR levels were lower and homocysteine levels were higher in IS patients compared with controls.

Discussion: Our results suggest that up-regulated miR-34a plays a role in the pathogenesis of IS, potentially through inhibiting MTHFR expression and increasing homocysteine in endothelial cells. Therefore, miR-34a might be a therapeutic target for IS.

导言:缺血性中风(IS)是全球关注的健康问题,通常与血脂异常和血管内皮功能障碍有关。据报道,缺血性中风患者血液样本中的微RNA-34a(miR-34a)被上调,但miR-34a和亚甲基四氢叶酸还原酶(MTHFR)在缺血性中风中的具体作用仍有待阐明:方法:我们对 143 名受试者进行了研究:方法:我们研究了 143 名受试者:71 名 IS 患者和 72 名健康对照组。培养人脐静脉内皮细胞(HUVECs),并用 miR-34a 模拟物、抑制剂或阴性对照组进行转染。通过定量反转录聚合酶链反应(qRT-PCR)对血清和 HUVEC 中 miR-34a 的表达进行了定量。使用 CCK-8 检测法和流式细胞术评估了 HUVEC 的活力和凋亡。通过 Western 印迹或酶联免疫吸附试验(ELISA)检测了 bcl-2、bax、cyt-c、裂解的 caspase 3、MTHFR 和同型半胱氨酸的表达水平。荧光素酶报告实验验证了 miR-34a 与 MTHFR 之间的关系。用酶联免疫吸附试验检测血清中 MTHFR 和同型半胱氨酸的水平:结果:IS 患者体内 MiR-34a 表达增加,抑制了 HUVECs 的活力,同时促进了其凋亡。过量表达 miR-34a 会上调促凋亡蛋白(bax、cyt-c 和裂解的 caspase 3),下调抗凋亡蛋白 bcl-2。MTHFR 被确定为 miR-34a 的下游靶标,miR-34a 过表达会降低其表达,而同型半胱氨酸水平则会升高。与对照组相比,IS 患者的 MTHFR 水平较低,而同型半胱氨酸水平较高:我们的研究结果表明,上调的 miR-34a 可能通过抑制 MTHFR 的表达和增加内皮细胞中的同型半胱氨酸,在 IS 的发病机制中发挥作用。因此,miR-34a可能是IS的治疗靶点。
{"title":"The Impact of miR-34a on Endothelial Cell Viability and Apoptosis in Ischemic Stroke: Unraveling the <i>MTHFR</i>-Homocysteine Pathway.","authors":"Lina Liang, Xueli Yi, Chunfang Wang, Li Su, Guijiang Wei","doi":"10.3138/cim-2024-2711","DOIUrl":"10.3138/cim-2024-2711","url":null,"abstract":"<p><strong>Introduction: </strong>Ischemic stroke (IS) is a global health concern, often tied to dyslipidemia and vascular endothelial dysfunction. MicroRNA-34a (miR-34a) was reported to be up-regulated in the blood samples of patients with IS, but the specific role of miR-34a and methylenetetrahydrofolate reductase (MTHFR) in IS remains to be elucidated.</p><p><strong>Methods: </strong>We studied 143 subjects: 71 IS patients, and 72 healthy controls. Human umbilical vein endothelial cells (HUVECs) were cultured and transfected with a miR-34a mimic, inhibitor, or negative control. The miR-34a expression in serum and HUVECs was quantified via quantitative reverse transcription polymerase chain reaction (qRT-PCR). Viability and apoptosis of HUVECs were assessed using CCK-8 assay and flow cytometry. The expression levels of bcl-2, bax, cyt-c, cleaved caspase 3, MTHFR, and homocysteine were measured by Western blot or enzyme-linked immunosorbent assay (ELISA). The relationship between miR-34a and MTHFR was verified by luciferase reporter assay. The levels of MTHFR and homocysteine in serum were examined by ELISA.</p><p><strong>Results: </strong>MiR-34a expression was increased in IS patients and inhibited viability of HUVECs while promoting their apoptosis. Overexpression of miR-34a up-regulated pro-apoptotic proteins (bax, cyt-c and cleaved caspase 3) and down-regulated anti-apoptotic protein bcl-2 in HUVECs. MTHFR was identified as the downstream target of miR-34a and its expression was reduced by miR-34a overexpression, while homocysteine levels increased. Consistently, MTHFR levels were lower and homocysteine levels were higher in IS patients compared with controls.</p><p><strong>Discussion: </strong>Our results suggest that up-regulated miR-34a plays a role in the pathogenesis of IS, potentially through inhibiting MTHFR expression and increasing homocysteine in endothelial cells. Therefore, miR-34a might be a therapeutic target for IS.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 3","pages":"27-37"},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Newsletter Fall 2024: Clinician Investigator Trainee Association of Canada (CITAC). 2024 年秋季通讯:加拿大临床研究员受训者协会(CITAC)。
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-01 DOI: 10.3138/cim-47-3-news
MohdWessam Al Jawhri, Salonee V Patel, Teija Bily, Yujin Suk, Robert X Lao
{"title":"Newsletter Fall 2024: Clinician Investigator Trainee Association of Canada (CITAC).","authors":"MohdWessam Al Jawhri, Salonee V Patel, Teija Bily, Yujin Suk, Robert X Lao","doi":"10.3138/cim-47-3-news","DOIUrl":"https://doi.org/10.3138/cim-47-3-news","url":null,"abstract":"","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 3","pages":"1-4"},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Application of CT Imaging Grading System in Upper Urinary Tract Calculi with Kidney Infection. CT 成像分级系统在上尿路结石合并肾脏感染中的临床应用
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-01 DOI: 10.3138/cim-2024-0107
Jianping Zhang, Lingfeng Zhu, Xiaoxia Wu, Haiying Chen, Runyang Pan, Zihuang Hong, Rongkai Lin

Purpose: This study aimed to establish a CT imaging grading system and explore its value in evaluating upper urinary tract calculi associated with kidney infections.

Methods: CT images of 126 patients with kidney infections caused by upper urinary tract calculi were retrospectively analyzed. The CT grading system was developed based on CT images. CT images were classified into 4 grades. General information, symptoms, and clinical findings of patients in different CT grades were analyzed. With the occurrence of systemic inflammatory response syndrome (SIRS) as the endpoint, univariate and multivariate analysis was conducted to analyze the risk factors of SIRS.

Results: Patients with fever or diabetes had higher CT grades, and the following examination data revealed significant differences across the various CT grades (P < 0.05): the white blood cell count, urine leucocytes count, CT1, CT2, maximum body temperature, duration of disease, the proportion of blood neutrophils, the size of stones, and levels of the C-reactive protein and procalcitonin. Only CT grading was statistically significant after multivariate analysis. According to the values of the partial regression coefficient (B), the higher the CT grade, the greater the risk of SIRS. The risk of SIRS was 4.472 times higher with each increment of the CT grade.

Conclusions: The CT grade is directly associated with clinical symptoms and the risk of SIRS.

目的:本研究旨在建立一套 CT 成像分级系统,并探讨其在评估与肾脏感染相关的上尿路结石方面的价值:方法:回顾性分析了126例由上尿路结石引起的肾脏感染患者的CT图像。根据 CT 图像建立了 CT 分级系统。CT 图像被分为 4 个等级。分析了不同 CT 分级患者的一般信息、症状和临床表现。以全身炎症反应综合征(SIRS)的发生率为终点,进行单变量和多变量分析,以分析SIRS的风险因素:发热或糖尿病患者的CT分级更高,以下检查数据在不同CT分级之间存在显著差异(P<0.05):白细胞计数、尿白细胞计数、CT1、CT2、最高体温、病程、血中性粒细胞比例、结石大小、C反应蛋白和降钙素原水平。经多变量分析,只有CT分级具有统计学意义。根据部分回归系数(B)的值,CT分级越高,发生SIRS的风险越大。CT分级每增加一级,SIRS的风险就增加4.472倍:结论:CT 分级与临床症状和 SIRS 风险直接相关。
{"title":"Clinical Application of CT Imaging Grading System in Upper Urinary Tract Calculi with Kidney Infection.","authors":"Jianping Zhang, Lingfeng Zhu, Xiaoxia Wu, Haiying Chen, Runyang Pan, Zihuang Hong, Rongkai Lin","doi":"10.3138/cim-2024-0107","DOIUrl":"10.3138/cim-2024-0107","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to establish a CT imaging grading system and explore its value in evaluating upper urinary tract calculi associated with kidney infections.</p><p><strong>Methods: </strong>CT images of 126 patients with kidney infections caused by upper urinary tract calculi were retrospectively analyzed. The CT grading system was developed based on CT images. CT images were classified into 4 grades. General information, symptoms, and clinical findings of patients in different CT grades were analyzed. With the occurrence of systemic inflammatory response syndrome (SIRS) as the endpoint, univariate and multivariate analysis was conducted to analyze the risk factors of SIRS.</p><p><strong>Results: </strong>Patients with fever or diabetes had higher CT grades, and the following examination data revealed significant differences across the various CT grades (<i>P</i> < 0.05): the white blood cell count, urine leucocytes count, CT1, CT2, maximum body temperature, duration of disease, the proportion of blood neutrophils, the size of stones, and levels of the C-reactive protein and procalcitonin. Only CT grading was statistically significant after multivariate analysis. According to the values of the partial regression coefficient (B), the higher the CT grade, the greater the risk of SIRS. The risk of SIRS was 4.472 times higher with each increment of the CT grade.</p><p><strong>Conclusions: </strong>The CT grade is directly associated with clinical symptoms and the risk of SIRS.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 3","pages":"7-17"},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Young Investigator Interview with CSCI Awardee, Dr. Kenneth Rockwood. 与 CSCI 获奖者 Kenneth Rockwood 博士的青年研究员访谈。
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-01 DOI: 10.3138/cim-47-3-award
Salonee V Patel, Kenneth Rockwood

[Figure: see text] Dr. Kenneth Rockwood is a Professor of Medicine in the Division of Geriatric Medicine and Neurology and Clinical Research Professor of Frailty and Aging at Dalhousie University, as well as an actively practising geriatric physician. Dr. Rockwood has made significant contributions to geriatric medicine and research, including his involvement in developing the Clinical Frailty Scale. He has been recognized with countless prestigious awards, the most recent being the Distinguished Scientist Award from the Canadian Society for Clinical Investigation.

[图:见正文] 肯尼斯-罗克伍德博士是达尔豪斯大学老年医学和神经病学部医学教授、虚弱与衰老临床研究教授,同时也是一名积极执业的老年医学医生。洛克伍德博士对老年医学和研究做出了重大贡献,包括参与开发临床虚弱量表。他获得过无数著名奖项,最近的奖项是加拿大临床研究学会颁发的杰出科学家奖。
{"title":"Young Investigator Interview with CSCI Awardee, Dr. Kenneth Rockwood.","authors":"Salonee V Patel, Kenneth Rockwood","doi":"10.3138/cim-47-3-award","DOIUrl":"10.3138/cim-47-3-award","url":null,"abstract":"<p><p>[Figure: see text] Dr. Kenneth Rockwood is a Professor of Medicine in the Division of Geriatric Medicine and Neurology and Clinical Research Professor of Frailty and Aging at Dalhousie University, as well as an actively practising geriatric physician. Dr. Rockwood has made significant contributions to geriatric medicine and research, including his involvement in developing the Clinical Frailty Scale. He has been recognized with countless prestigious awards, the most recent being the Distinguished Scientist Award from the Canadian Society for Clinical Investigation.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 3","pages":"5-6"},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global Trends and Frontier in Research on Pancreatic Alpha Cells: A Bibliometric Analysis from 2013 to 2023. 胰腺α细胞研究的全球趋势和前沿:2013年至2023年文献计量分析》。
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-06-01 DOI: 10.3138/cim-2024-2744
Teng Guo, Haoling Zhang, Yunpeng Luo, Xi Yang, Lidan Wang, Guangde Zhang

Purpose: Over the past 20 years, much of the research on diabetes has focused on pancreatic beta cells. In the last 10 years, interest in the important role of pancreatic alpha cells in the pathogenesis of diabetes, which had previously received little attention, has grown. We aimed to summarize and visualize the hotspot and development trends of pancreatic alpha cells through bibliometric analysis and to provide research direction and future ideas for the treatment of diabetes and other islet-related diseases.

Methods: We used two scientometric software packages (CiteSpace 6.1.R6 and VOSviewer1.6.18) to visualize the information and connection of countries, institutions, authors, and keywords in this field.

Results: A total of 532 publications, published in 752 institutions in 46 countries and regions, were included in this analysis. The United States showed the highest output, accounting for 39.3% of the total number of published papers. The most active institution was Vanderbilt University, and the authors with highest productivity came from Ulster University. In recent years, research hotspots have concentrated on transdifferentiation, gene expression, and GLP-1 regulatory function. Visualization analysis shows that research hotspots mainly focus on clinical diseases as well as physiological and pathological mechanisms and related biochemical indicators.

Conclusions: This study provides a review and summary of the literature on pancreatic alpha cells through bibliometric and visual methods and shows research hotspot and development trends, which can guide future directions for research.

目的:在过去 20 年中,有关糖尿病的大部分研究都集中在胰腺 beta 细胞上。近 10 年来,人们对胰腺α细胞在糖尿病发病机制中的重要作用越来越感兴趣,而胰腺α细胞以前很少受到关注。我们的目的是通过文献计量学分析,总结胰岛α细胞的研究热点和发展趋势,为糖尿病及其他与胰岛相关疾病的治疗提供研究方向和未来思路:我们使用两个科学计量学软件包(CiteSpace 6.1.R6和VOSviewer1.6.18)对该领域的国家、机构、作者和关键词的信息和联系进行了可视化分析:本次分析共收录了 46 个国家和地区的 752 家机构发表的 532 篇论文。美国的论文数量最多,占发表论文总数的 39.3%。最活跃的机构是范德比尔特大学,产量最高的作者来自阿尔斯特大学。近年来,研究热点主要集中在转分化、基因表达和GLP-1调控功能等方面。可视化分析表明,研究热点主要集中在临床疾病以及生理病理机制和相关生化指标上:本研究通过文献计量学和可视化方法对胰腺α细胞的相关文献进行了回顾和总结,并展示了研究热点和发展趋势,为今后的研究方向提供了指导。
{"title":"Global Trends and Frontier in Research on Pancreatic Alpha Cells: A Bibliometric Analysis from 2013 to 2023.","authors":"Teng Guo, Haoling Zhang, Yunpeng Luo, Xi Yang, Lidan Wang, Guangde Zhang","doi":"10.3138/cim-2024-2744","DOIUrl":"10.3138/cim-2024-2744","url":null,"abstract":"<p><strong>Purpose: </strong>Over the past 20 years, much of the research on diabetes has focused on pancreatic beta cells. In the last 10 years, interest in the important role of pancreatic alpha cells in the pathogenesis of diabetes, which had previously received little attention, has grown. We aimed to summarize and visualize the hotspot and development trends of pancreatic alpha cells through bibliometric analysis and to provide research direction and future ideas for the treatment of diabetes and other islet-related diseases.</p><p><strong>Methods: </strong>We used two scientometric software packages (CiteSpace 6.1.R6 and VOSviewer1.6.18) to visualize the information and connection of countries, institutions, authors, and keywords in this field.</p><p><strong>Results: </strong>A total of 532 publications, published in 752 institutions in 46 countries and regions, were included in this analysis. The United States showed the highest output, accounting for 39.3% of the total number of published papers. The most active institution was Vanderbilt University, and the authors with highest productivity came from Ulster University. In recent years, research hotspots have concentrated on transdifferentiation, gene expression, and GLP-1 regulatory function. Visualization analysis shows that research hotspots mainly focus on clinical diseases as well as physiological and pathological mechanisms and related biochemical indicators.</p><p><strong>Conclusions: </strong>This study provides a review and summary of the literature on pancreatic alpha cells through bibliometric and visual methods and shows research hotspot and development trends, which can guide future directions for research.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 2","pages":"23-39"},"PeriodicalIF":1.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical and Investigative Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1